IMMray™ PanCan-d test performance in detecting early stage pancreatic cancer in high risk symptomatic patients

The test performance of a blood based IMMray™ PanCan-d biomarker signature together with CA 19-9 was recently evaluated in clinical retrospective study. The study was designed to evaluate detection of early stage (stage I&II) pancreatic ductal adenocarcinoma (PDAC) in high risk patients with non-specific but concerning symptoms for PDAC. In total, 433 patient serum samples, including 202 PDAC stage I-IV, 89 early stage PDAC stage I&II, and 231 early symptomatic controls were analyzed with IMMray™ PanCan-d biomarker signature and CA 19-9 assay. All samples were freshly collected at seven reference sites in USA and Europe. The results showed that early stage PDAC I&II could be separated from symptomatic controls with specificity of 92% and sensitivity of 80%, and PDAC stage I-IV was differentiated with specificity of 92% and sensitivity of 81%. Detecting pancreatic cancer as early as possible in high risk symptomatic patients is a challenging but extremely important achievement that could support clinicians in providing accelerated and correct diagnosis to the patients.

Publication History

Article published online:
07 September 2021